PRIMARY OBJECTIVES:. I. To evaluate recurrence-free survival (RFS) between patients randomized to receive post-operative adjuvant ipilimumab given at either 10 mg/kg (high dose ipilimumab; HIP) or 3 mg/kg (low dose ipilimumab: LIP) versus those randomized to receive high-dose interferon alfa-2b (HDI) utilizing a hierarchical design assessing HIP versus HDI first and LIP versus HDI second (if the first comparison is significant).. II. To evaluate overall survival (OS) between patients randomized to receive post-operative adjuvant ipilimumab given at either 10 mg/kg (HIP) or 3 mg/kg (LIP) versus those randomized to receive HDI utilizing a hierarchical design assessing HIP versus HDI first and LIP versus HDI second (if the first comparison is significant).. SECONDARY OBJECTIVES:. I. To evaluate safety and tolerability of post-operative adjuvant ipilimumab therapy given at either 10 mg/kg (HIP) or 3 mg/kg (LIP).. II. Among patients enrolled by Clinical Community Oncology programs (CCOPs), to compare ...
The safety and efficacy of peginter-feron was studied in 1,219 adult patients with chronic hepatitis C infection, including patients with genotype 1 (70%) and patients with a high level of titers (,2 million copies/mL). Patients were randomized to interferon alfa-2b 3 million units three times a week or 0.5, 1, and 1.5 mcg/kg of pegin-terferon weekly. The patients were treated for 48 weeks and followed for another 24 weeks posttreatment. The primary end point was undetectable HCV RNA and normalization of liver function tests. The overall response rate was similar for the 1- and 1.5-mcg/kg peginterferon groups. However, these groups had significantly better response rates compared with the interferon alfa-2b group. The reported virologic response was 25% for peginterferon 1 mcg/kg, 18% for 0.5 mcg/kg, and 12% for interferon alfa-2b 3 million units. Additionally, 29% of peginterferon patients experienced normalization of liver function tests compared with 18% of the interferon alfa-2b group. In ...
Chronic hepatitis C is a prevalent condition, and the main cause of chronic liver diseases, including cirrhosis and cancer. Nowadays, interferon-alfa in combination with ribavirin is the main treatment option for this condition. In the last years, interferon molecule has been modified in order to improve tolerance into pegylated interferon.. Interferon-alfa has been associated with a high prevalence of psychiatric side effects, especially major depression (up to 25% of the cases), which is one of the main concerns about using this treatment. In fact, major depression is one of the main reasons of treatment withdrawal and treatment failure.. Major depression induced by interferon-alfa can be successfully treated with antidepressants, but we dont know if antidepressants can also prevent the development of major depression, and if this can be a safe intervention. In the literature, there is only one controlled trial about this issue, in cancer patients, and some open studies in hepatitis C.. In ...
This phase II trial examined the efficacy and tolerability of girentuximab [monoclonal antibody G250; WX G250] + low-dose interferon alpha-2a as adjuvant
Two forms of recombinant interferon-alpha (IFN-alpha2a and IFN-alpha2b) have been approved by the Food and Drug Administration for
This trial investigated Romiplostim with Telaprevir, Ribavirin, and Peg Interferon-alfa 2a to assess effect to Optimize SVR in patients with Thrombocytopenic
The purpose of the study is to determine whether interferon-alpha is effective in the treatment of p48 Positive patients with HCC after curative resecti
The goal of this clinical research study is to find the best dosing schedule of a combined treatment of PEG Intron® (pegylated Interferon-alfa 2b) plus a peptide vaccine (gp100) that may help improve immune response in patients that had Stage II or Stage III melanoma and are free of the disease. The safety and tolerability of this drug combination will also be studied. Researchers also want to collect long-term follow-up information.
MEASUREMENTS: Serum hepatitis C virus (HCV) RNA detected by polymerase chain reaction (PCR); HCV genotyping determined by line probe assay; liver histologic studies; liver HCV RNA detected by PCR on frozen liver tissue samples (in 27 patients); and repeated measurements of serum alanine aminotransferase (ALT) levels. Liver biopsy was done before treatment in all 80 patients, and at least one biopsy was done in 69 patients 1 to 6 years after treatment. RESULTS: The 80 patients had follow-up 1 to 7.6 years (mean +/- SD, 4.0 +/- 2.0 years) after interferon-alpha treatment. The follow-up period was 1, 2, 3, 4, 5, 6, and more than 6 years in 11, 13, 14, 18, 10, 12, and 2 patients, respectively, after the end of therapy. During the entire follow-up period, 93% (95% CI, 84% to 97%) of patients had persistently normal serum ALT levels. Serum HCV RNA remained undetectable in 96% (CI, 89% to 99%) of patients. A comparison of liver histologic findings before and 1 to 6.2 years after interferon-alpha ...
A total of eight eyes of 8 patients (mean age of 69 y/o) with a clinical diagnosis of unilateral giant OSSN were managed with interferon alpha-2b. Six patients received topical therapy (1 million IU/mL) 4 times per day for a minimum of 3 months for immunotherapeutic purposes and 2 patients received subconjunctival therapy (3 million IU/mL) single dose per week for 1 month for immunoreduction. The median time to resolution was 5 months (range, 1.5-6 months) and the median follow-up was 22 months (range, 6-28 months). Despite the dramatic clinical response, all patients continued with topical interferon alpha-2b at least 1 month beyond complete clinical resolution. The two cases in which immunoreduction was successfully achieved, were scheduled for a lesion excision with a no-touch technique followed by cryotherapy and amniotic membrane to cover the large excision area. There has been no recurrence during follow-up. Conclusions : In cases of giant OSSN interferon alpha-2b can successfully reduce ...
RESULTS: During a mean follow-up of 68 months, HBsAg loss occurred in 32 patients, including 16 (8%) of 196 untreated patients (mean annual incidence 0.8%), 8 (10%) of 82 interferon (IFN) alpha-treated patients and eight patients who had been treated with other antivirals or steroids. The 5-yr probability of HBsAg loss was 4% and 16% for untreated and IFN-treated patients, respectively (p = 0.0001). Coxs regression analysis identified hepatitis B e antigen-positivity at entry as the sole independent prognostic factor for HBsAg loss. Of the 32 patients who lost HBsAg, one (3%) subsequently developed hepatocellular carcinoma (HCC) and died, whereas, among the patients who remained HBsAg-positive, 11% developed HCC and 20% had died. The probability of HCC appearance was lower (p = 0.0137) and survival was longer (p = 0.0006) in patients who cleared HBsAg compared with patients with HBsAg persistence ...
Gentaur molecular products has all kinds of products like :search , Prospecbio \ Polyclonal Rabbit Anti Human Interferon-Alpha 2a IFNA2A \ ant-034 for more molecular products just contact us
Definition of Interferon-alpha 2b with photos and pictures, translations, sample usage, and additional links for more information.
... , includes Interferon Alfa-2a, Recombinant side effects, interactions, indications
Neuropsychiatric symptoms are commonly related to interferon alpha treatment. The paper summarises the current knowledge about their aetiology, course
Interferon-α (IFN-α, also known as IFN-alpha, IFN-a, IFNA and Interferon-alpha) is a type I interferon and exists as 13 subtypes: IFN-α 1, 2, 4, 5, 6, 7, 8, 10, 13, 14, 16, 17 and 21. Like the other subtypes, interferon-α2 (IFN-α2, also known as IFN-alpha2, IFN-a2, IFNA2 and Interferon-alpha2) is mainly produced by virus infected cells after sensing the presence of danger signals such as viral DNA or RNA. The binding of IFN-α2 to its receptor thus initiates an anti-viral response, but also anti-tumor effects have been shown. Being the first to be discovered, IFN-α2 is the most widely studied subtype and it has been used as a cytokine therapy versus hepatitis C virus infections.. ...
Induction doses of interferon-alpha-2a in combination with ribavirin and/or amantadine for the treatment of chronic hepatitis C in non-responders to interferon
interferon-alpha B-D: a hybrid IFN constructed with an N-terminal part & a C-terminal part of IFNalpha B (-alpha1) combined with an IFNalpha D (-alpha8)-derived middle part (IFNalpha BDBB)
Interferon-alpha B2 (IFN-a8) (mPEG-ALD), 1 mg. Clusterin also names Apoliprotein J is a 75-80 kD disulfide-linked heterodimeric protein containing about 30% of N-linked carbohydrate rich in sialic acid but truncated forms targeted to the nucleus have
... ... ... ... ...,Anadys,Pharmaceuticals,Receives,FDA,Clearance,of,Phase,II,Protocol,to,Study,ANA598,in,Combination,With,Interferon-Alpha,and,Ribavirin,in,HCV,Patients,biological,advanced biology technology,biology laboratory technology,biology device technology,latest biology technology
The anti-viral cytokine interferon-alpha is expressed in acute MS lesions and associated with the presence of Epstein-Barr virus ...
This observational study will evaluate the safety and efficacy of Avastin (bevacizumab) in combination with interferon alpha-2a as first-line treatment
Interferon alpha-2 Monoclonal Antibody from Invitrogen for Western Blot and Immunoprecipitation applications. This antibody reacts with Human samples. Clone: 17G6. Supplied as 100 µL purified antibody (1 mg/ml) in HEPES with 0.15M NaCl, 0.01% BSA, 50% glycerol and 0.03% sodium azide.
inflammation may also be associated with general flu-like symptoms including: * fever * chills * fatigue/loss of energy * headaches * loss of appetite * muscle stiffness
Visit your doctor or health care professional for regular checks on your progress. You will need regular blood checks.. Do not change brands of medicine without consulting your doctor or health care professional. Different brands of medicine can act differently in your body. Check with your pharmacist if your refills do not look like your original product.. You may get drowsy or dizzy. Do not drive, use machinery, or do anything that needs mental alertness until you know how this medicine affects you. Alcohol can make you more drowsy or dizzy, increase confusion and lightheadedness. Avoid alcoholic drinks.. This medicine can cause flu-like symptoms and make you feel generally unwell. Report any side effects, but continue your medicine even though you feel ill, unless your doctor or health care professional tells you to stop. If you get a fever or sore throat that does not go away after the first few weeks of treatment, do not treat yourself. Call your doctor or health care professional as soon ...
SEA033Si, ELISA Kit for Interferon Alpha (IFNa), 干扰素α(IFNa)检测试剂盒(酶联免疫吸附试验法), IFNA1; IFL; LeIF D; IFN; IFN-Alpha; IFNA13; IFN-A; IFNAP22; IFN-Alpha 1b; Interferon Alpha 1b; Interferon, Leukocytic; IFN, Leukocyte; Interferon alpha-D | 仅供体外研究使用,不用于临床诊断!请索取进口关税税单及报关单!
Jim and I weighed the pro and we weighed the cons of Interferon vs a clinical trial. The Interferon leaves allot to be desired in the immediate "Quality of Life" scenario but we know it has a high chance of adding an additional disease-free year to my life. The clinical trials are a gamble. Some work, some dont ... and most trial are 2 years of study with no guarantee ...
HIV-1 isolate R3A Nef mutants G2, WL58, RR106, LL165, E160NNSLL165, and DD175 fail to induce release of IFN-alpha in pDCs, suggesting that the Nef function responsible for CD4 downregulation is crucial for pDCs stimulation by ...
Flu like symptoms can be nerve-wracking. Call us today to set up an appointment to get your flu like symptoms evaluated. We are dedicated to your well-being.
well a few years ago I had flu-like symptoms very badly and then I developed a rash on my hands and chest after a while. The doctor tested for mono and sure enough it was the last thing I was tested for and that is what it was. Sadly the only thing I could do was take the antibiotic and aveeno anti-itch cream and let the rest take its course. It lasted about two months with the flu and the rash went away in a week or so. good luck, feel better. *m ...
Pegylated interferon alpha 2b is used in the treatment of chronic hepatitis b virus (hbv) infection,chronic hepatitis c virus (hcv) infection,multiple myeloma(blood cancer),follicular lymphoma,hairy cell leukemia.get complete information about pegylated interferon alpha 2b including usage, side effects, drug interaction, expert advice along with medicines associated with pegylated interferon alpha 2b at 1mg.com
Cooksley et al 2003 is an open-label trial, which assessed the efficacy and safety of different doses of peginterferon alfa-2a vs. interferon alfa-2a 4.5 MIU for 24 weeks of therapy followed by 24 weeks of treatment-free follow up in 194 interferon-naïve patients with chronic hepatitis B. There was a non-significant higher incidence of serious adverse events in the peginterferon alfa-2a 180μg/week group (8.6%) as compared with interferon 4.5 MIU /three times a week group (4%). The most common causes of SAEs were gastrointestinal disorders and infections. There was no difference in virologic or immunologic outcomes (such as loss of DNA or seroconversion) between peginterferon alfa-2a 180μg/wk and interferon alfa-2a 4.5 MIU group. The basis of choosing 180μg/week dose as the recommended dose is not clear since the efficacy in terms of surrogate outcome measures did not differ among the different peginterferon regimens (90, 180 and 270μg/week) and the number of patients who required dose ...
A study of patients with chronic hepatitis C and a history of hepatocellular carcinoma treated with pegylated interferon alpha-2b plus ribavirin showed a high risk of recurrence, according to data presented at IDWeek 2012.
PubMed journal article Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infectio were found in PRIME PubMed. Download Prime PubMed App to iPhone or iPad.
Life-threatening and fatal neuropsychiatric reactions may occur with peginterferon alfa-2b use, including suicide, suicidal ideation, homicidal ideation and depression.. Depression was reported by 59% of patients in clinical trials. Post-marketing neuropsychiatric reactions have also been reported, including hallucinations, psychosis, aggression, bipolar mania and encephalopathy. Patients taking peginterferon alfa-2b should be advised to report any of these symptoms to their health care provider, and providers should monitor their patients for these symptoms. Suicidal or homicidal ideation should result in immediate discontinuation of peginterferon alfa-2b.). Additional serious adverse events associated with peginterferon alfa-2b treatment include:. ...
TY - JOUR. T1 - A Decade of Trials of Interferon-Alpha for Chronic Hepatitis C. A Meta-Regression Analysis. AU - Attanasio, Massimo. AU - Tinè, Fabio. AU - Russo, Francesco. PY - 2005. Y1 - 2005. N2 - The most relevant randomized controlled trials of interferon-alpha (IFN) for naive patients with chronic hepatitis C (CHC) published in a decade, just before appearance of pegylated IFN trials in 2000, were included in this paper. Its purpose is to review the relationship between sustained biochemical response in active versus control group versus usual clinical variables as IFN regimens, cirrhosis, genotype and versus less frequently addressed variables as funding, methodological quality or location of principal author. Meta-analysis estimates of global treatment effect varied according to trial design: group 1=IFN versus placebo/no treatment, 32 RCTs, 2499 pts, OR 9.5 (6.3-14.2); group 2a=comparison of IFN schedules, 43 RCTs, 7454 pts, OR 1.6 (1.4-1.9); group 2b=IFN+other drugs versus standard ...
ClinicalTrials.gov summary of Structured Treatment Interruptions With or Without Pegylated Interferon Alpha for HIV-Infected Patients After Prolonged Viral Suppression
The 24-week analysis from this ongoing 48-week phase IIb clinical trial in treatment-naive HCV patients included data from the following five randomized treatment arms, all involving dosing regimens of valopicitabine, administered once-daily, in combination with pegylated interferon alfa-2a (Pegasys) 180 _g per week: (A, n=34) pegylated interferon beginning on day 8 plus valopicitabine ramping from 400 mg to 800 mg beginning at day 29-32, followed by dosing at 800 mg; (B, n=34) valopicitabine 200 mg beginning on day 1 plus pegylated interferon beginning on day 8; (C, n=34) valopicitabine ramping from 400 mg to 800 mg from day 1-6, followed by dosing at 800 mg plus pegylated interferon beginning on day 8; (D, n=36) valopicitabine 800 mg beginning on day 1 plus pegylated interferon beginning on day 8; and (E, n=35) valopicitabine 800 mg plus pegylated interferon, both beginning on day 1 ...
Hepatitis C virus treatment with pegylated interferon-alfa therapy leading to generalized interstitial granuloma annulare and review of the literature.: We disc
IFN-α is known as the only established treatment for chronic hepatitis type C. The reason why not all patients respond to IFN therapy is not clear. However, patients characteristics, administration schedule of IFN therapy and molecular biological properties of HCV are thought to be some of the factors influencing the outcome of IFN therapy. Among them, shorter duration of disease, absence of cirrhosis, prolonged therapy with higher doses, a lower histologic activity index (HAI), HCV genotype 2 and lower level of serum HCV RNA have been associated with better response to IFN4,6,11-12,23-25).. In this study, demographic profiles, biochemical data and histological findings before IFN therapy had no important effect on the response rate to IFN, as reported previously26).. Although the shorter duration of disease is reported to predict a better response to IFN therapy12), we did not include it among possible variables that can influence the response to IFN therapy in this study, because the time of ...
Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. ...
Get an overview of PEGASYS (peginterferon alfa-2a injection, solution), including warnings and precautions, directions, and the names of other drugs and products that include the same medication.
Sigma-Aldrich offers abstracts and full-text articles by [Emily Charrier, Paulo Cordeiro, Rose-Marie Brito, Michaël Harnois, Samira Mezziani, Sabine Herblot, Françoise Le Deist, Michel Duval].
Chronic hepatitis C can lead to decompensated liver disease and its catastrophic complications. Asymptomatic nature of disease at earlier stages results in delay in diagnosis and treatment. With introduction of interferon (IFN) therapy over last 2 decades, this infection is now amenable to treatment. Once ribavirin was added and later on with development of Pegylated interferon, sustained viral response (SVR) has increased up to 80% in patients with genotype 2 and 3.1 Comparatively lesser benefit is seen in other genotypes i.e. 1, 4, 5 and 6 and treatment duration recommended is also 1 year as compared to 6 months in genotype 2 and 3.2 Treatment options for non-responders or relapsers are either Pegylated interferon in those treated with standard IFN previously,3 consensus interferon or just follow up for those with failure with Pegylated IFN therapy.4 ...
Interferon alfa-2b is made from human proteins. Interferons help your bodys immune system respond to bacteria, viruses, cancer, or other invading substances. Interferon alfa-2b is used to treat hairy cell leukemia, malignant melanoma, follicular lymphoma, Kaposis sarcoma caused by AIDS, and certain types of genital...
We performed a meta-analysis of the AIDS Clinical Trials Group (ACTG) A5071, AIDS Pegasys Ribavirin International Coinfection Trial (APRICOT), and Agence Nationale de Recherches sur le SIDA (ANRS) HCO2-RIBAVIC HCV treatment studies in HIV/HCV coinfection, conducted by different clinical trial networks between 2000 and 2003. Subject-level data were obtained for each study. Only subjects who initiated HCV treatment were included in the analysis. Detailed inclusion criteria, study design, and criteria for treatment discontinuation and dose modifications are described in detail elsewhere.[4-6] In A5071, subjects were randomized to receive 180 μg of peginterferon alfa-2a weekly for 48 weeks and dose-escalated ribavirin or 6 million IU of interferon alfa-2a 3 times weekly for 12 weeks followed by 3 million IU 3 times weekly for 36 weeks with dose-escalated ribavirin.[5] Ribavirin was administered as 600 milligrams per day for 4 weeks, 800 milligrams per day for 4 weeks, and then 1000 milligrams per ...
Link to Pubmed [PMID] - 19651532. Cytokine Growth Factor Rev. 2009 Aug;20(4):283-95. Immune recognition of virus-associated molecules by Toll-like receptors (TLRs) and/or RIG-I-like receptors (RLRs) triggers intracellular signaling cascades that converge on the activation of interferon regulatory factors - particularly IRF3 and IRF7, leading to the transcriptional induction of type 1 interferon genes. This review summarizes new data describing how these factors regulate the temporal and quantitative differences in the expression of the multigenic IFN-A family. The distinctive DNA-binding features of IRF3 and IRF7 affect the selectivity and affinity of these factors for IFN-A promoters; modification of the ratio of promoter-bound IRF3 and IRF7 during virus infection may influence both transcriptional activation and repression of IFN-A genes. This review also summarizes the structural differences between IFN-beta and different IFN-alpha subtypes, their interaction with their common receptor IFNAR, ...
While HCV vaccine is unavailable, effective treatment options exist, including groundbreaking new types of pharmacotherapy. Standard treatment has involved combination therapy with interferons (such as PegIntron, Pegasys, Infergen, Intron A) and ribavirin (such as Copegus, Rebetol, Ribasphere). The related success rates have recently been improved with the addition of polymerase and protease inhibitors to standard pegylated interferon/ribavirin combination therapy. Breakthrough treatments now available that have the potential to dramatically improve the incidence of HCV infection include Olysio (a protease inhibitor) and Sovaldi (a polymerase inhibitor), both which received FDA approval in the last quarter of 2013. In addition to receiving pharmacotherapy, patients with HCV infection should be educated about topics that are relevant to their condition, such as informing them about the low but present risk for transmission through unprotected sex, and that they should not donate blood, organs, ...
Natural human interferon alpha 2 (IFN-alpha 2) was isolated from a preparation of partially purified human leucocyte IFN by monoclonal-antibody immunoaffinity chromatography. The purified protein had a specific activity of 1.5 x 10(8) i.u./mg; it was estimated to constitute 10-20% of the total antiviral activity of leucocyte IFN. N-Terminal amino-acid-sequence analysis identified the subspecies IFN-alpha 2b and/or IFN-alpha 2c, whereas IFN-alpha 2a was not detectable. The structure of natural IFN-alpha 2 was found to differ from that of its recombinant (Escherichia coli-derived) equivalent. First, reverse-phase h.p.l.c. showed that natural IFN-alpha 2 was significantly more hydrophilic then expected. Secondly, the apparent molecular mass of the natural protein determined by SDS/PAGE was higher than that of recombinant IFN-alpha 2; incubation under mild alkaline conditions known to eliminate O-linked carbohydrates resulted in a reduction of the apparent molecular mass to that of the recombinant ...
... ,ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories client,medicine,medical supply,medical supplies,medical product